Richard Bucala, MD, PhD

Professor of Medicine (Rheumatology), of Epidemiology (Microbial Diseases) and of Pathology; Deputy Chief, Section of Rheumatology

Departments & Organizations

Internal Medicine: CPIRT - Pulmonary Infection Research and Treatment | Diabetes Research Center | Interstitial Lung Disease (ILD) Program | Liver Center | Rheumatology: Rheumatic Diseases Research Core | Rheumatology, Allergy, & Clinical Immunology

Pathology: Experimental Pathology Graduate Program

School of Public Health: Epidemiology of Microbial Diseases

Faculty Research


Skin Diseases Research Center, Yale

Stem Cell Center, Yale

Yale Cancer Center: Cancer Immunology

Yale Combined Program in the Biological and Biomedical Sciences (BBS): Microbiology: Immunology & Host Response; Parasites | Molecular Medicine, Pharmacology, and Physiology: Hematology, Vascular Biology and Inflammation; Human Disease Pathology, Physiology and Intervention; Receptors and Signal Transduction; Virology and Immunology

Yale Medicine

Global Health Studies: Infectious Diseases

Office of Cooperative Research

Yale Institute for Global Health


Richard Bucala, MD, PhD, is Deputy Chief of the Section of Rheumatology and Professor of Medicine, Pathology, and Epidemiology & Public Health.  He studies the mechanisms by which protective immune responses lead to immunopathology, focusing on MIF-family cytokines and their genetics, which his group first cloned and characterized experimentally.  Currently, his laboratory is leading multidisciplinary efforts to develop immunotherapies tailored to an individual’s genetic makeup. An anti-MIF developed by the group is undergoing clinical testing in oncology, and an anti-MIF receptor antibody, recently FDA approved, is under evaluation in SLE. Dr. Bucala also is credited with the discovery of the fibrocyte, which is being targeted therapeutically in different fibrosing disorders.  He is a co-founder of Cytokine Networks and of MIFCOR, a biotechnology startup begun as a student-advised project.  Dr. Bucala was elected to the American Society for Clinical Investigation and the Association of American Physicians. He is the Editor-in-Chief of Arthritis & Rheumatology and has served on numerous advisory boards for the NIH, the pharmaceutical industry, academia, and private foundations.

Education & Training

MD Cornell College (1986)
PhD Rockefeller University (1985)
BS Yale University (1979)
MS Yale University (1979)
Fellow Hospital for Special Surgery
Resident Brigham & Women's Hospital/Harvard Medical School
Visiting Fellow Institut Pasteur, Paris

Honors & Recognition

  • American Association of Physicians (2009)

  • American Society for Clinical Investigation (1996)

Professional Service

  • Arthritis & Rheumatology (2016 - Present) Editor-in-Chief

  • Journal of Immunology (2010 - Present) Associate Editor

  • Alumni Schools Committee (2008 - Present)

  • NIH (2006 - Present) NIH Biodefense and Chemical Countermeasures


  • Genetic studies of human host susceptibility to tuberculosis South Africa (2010)

    Genetic studies of human host susceptibility to tuberculosis

  • Genetic Susceptibility to Leishmania Colombia (2008)

    The Bucala group is investigating the genetic susceptibility to the parasitic infection Leishmania in collaboration with researchers in Cali, Colombia.

  • Genetic studies of human host susceptibility to Leishmaniasis Cali, Colombia (2005)

    Genetic studies of human host susceptibility to Leishmaniasis

  • Genetic epidemiology studies Kenya; Zambia (2003)

    Role of innate immunity in malaria infection

Edit this profile